BUZZ-Novo Nordisk down as US FDA staff flags concern over use of weekly insulin

Reuters05-22

** U.S.-listed shares of Danish obesity drugmaker Novo Nordisk down 1.6% at about $133

** FDA staff said data showed use of Novo's long-acting weekly insulin had an increased risk of low blood sugar in patients with type 1 diabetes

** A panel of independent FDA advisers will meet on Friday to review and discuss the safety and effectiveness of company's insulin icodec — an under-the-skin injection

** The FDA is not obligated to follow the advisory panel's recommendations, but it usually does

** Separately, a large fire that broke out at a Novo office building in Denmark on Wednesday has been brought under control, the local fire department says

** Including session's fall, stock up ~28.5% YTD

(Reporting by Pratik Jain in Bengaluru)

((Pratik.Jain@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment